Press Releases

Advanced Search
  • Jun 11, 2019
    Commercial availability of NOCITA 10 mL vial size anticipated by fall 2019

    Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food...

  • Jun 7, 2019
    Stockholders Elect All Class III Directors and Approve Proposals

    Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...

  • May 8, 2019
    Continued revenue growth across portfolio of marketed pet therapeutics

    Aratana recorded $7.4 million in total revenues for the first quarter of 2019, including $2.5 million in NOCITA net product sales, $1.5 million in ENTYCE net product sales and $3.4 million in licensing and collaboration revenue from Elanco for GALLIPRANT.

  • May 7, 2019

    The Company plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City.

  • Apr 26, 2019
    Elanco announces formation of commercial team dedicated to veterinary specialty business

    The Company announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. If the proposed agreement is consummated, the Aratana field force would transition into this commercial team.

Show 5102550100 per page